Benjamin Landry Sells 6,057 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 6,057 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $3.94, for a total transaction of $23,864.58. Following the completion of the transaction, the general counsel now owns 151,125 shares in the company, valued at $595,432.50. The trade was a 3.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Health Catalyst Stock Up 1.5%

Shares of NASDAQ:HCAT traded up $0.06 on Monday, hitting $4.16. 535,112 shares of the company traded hands, compared to its average volume of 603,935. The stock has a 50 day simple moving average of $3.95 and a 200-day simple moving average of $5.34. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $289.54 million, a PE ratio of -3.08 and a beta of 1.53. Health Catalyst, Inc. has a 52 week low of $3.49 and a 52 week high of $9.24.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Piper Sandler cut their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. KeyCorp decreased their target price on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Evercore ISI lowered Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday, April 9th. Royal Bank of Canada reduced their price target on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 27th. Finally, Canaccord Genuity Group lowered their price objective on Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst has a consensus rating of "Moderate Buy" and an average target price of $8.00.

Institutional Trading of Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of HCAT. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 99.1% in the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company's stock worth $47,279,000 after buying an additional 5,195,686 shares in the last quarter. Impax Asset Management Group plc raised its holdings in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after acquiring an additional 195,525 shares during the last quarter. Daventry Group LP raised its holdings in Health Catalyst by 3.8% in the 4th quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock worth $17,742,000 after acquiring an additional 91,878 shares during the last quarter. Nepsis Inc. lifted its position in Health Catalyst by 2,072.1% in the 1st quarter. Nepsis Inc. now owns 2,090,812 shares of the company's stock valued at $9,471,000 after acquiring an additional 1,994,555 shares in the last quarter. Finally, Alyeska Investment Group L.P. lifted its holdings in shares of Health Catalyst by 74.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after purchasing an additional 861,150 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.